Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study.

Paolo CameliMaria AlianiElena AltieriPietro BraccialeLuisa BrussinoMaria Filomena CaiaffaGiorgio Walter CanonicaCristiano CarusoStefano CentanniMaria D'AmatoFausto De MicheleStefano Del GiaccoFederico Raimondi Girolamo Pelaia Rogliani PaolaMicaela RomagnoliPietro SchinoJan Walter SchroederGianenrico SennaAlessandra VultaggioMarco BenciSilvia BoarinoFrancesco Menzella

Published in: Journal of asthma and allergy (2024)

Benralizumab promotes durable and profound clinical benefits in naïve and bio-experienced groups, indicating that a nearly complete depletion of eosinophils is highly beneficial in the control of SEA, independently of previous biologic use.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
randomized controlled trial
rheumatoid arthritis
systematic review
chronic obstructive pulmonary disease
prognostic factors
lung function
intellectual disability
cystic fibrosis
autism spectrum disorder